We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Batavia Receives Grant to Support Vaccine Availability in Developing Countries
News

Batavia Receives Grant to Support Vaccine Availability in Developing Countries

Batavia Receives Grant to Support Vaccine Availability in Developing Countries
News

Batavia Receives Grant to Support Vaccine Availability in Developing Countries

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Batavia Receives Grant to Support Vaccine Availability in Developing Countries"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Despite many advances in manufacturing technologies in recent years, cost of manufacturing can still present a significant hurdle in the global supply of essential vaccines, such as Polio and Rotavirus vaccines. The work funded by this grant will reduce manufacturing costs of these key vaccines. In its advanced cell-line experience, Batavia Biosciences collaborates with Proventus Bio and their whole genome RNAi screening technology. The RNAi screening data allows Batavia Biosciences to utilize its gene editing technology and cell line expertise. This way, a range of new cell substrates can be generated which will be assessed for its manufacturing performance. Chris Yallop (CSO Batavia Biosciences) expects that “the new cell substrates can significantly increase production yield and thus enhance vaccine availability against reduced costs”.

Menzo Havenga (CEO Batavia Biosciences) adds: “It is extremely rewarding to be working with other best in class partners on a technology development that will have such significant impact in vaccine supply for those in need”.

Advertisement